Health Canada has officially ended the Foreign Site Reference Number (FSRN) process, which has removed the option of using this for demonstrating foreign Good Manufacturing Practices (GMP) compliance under the Natural Health Product (NHP) Site Licensing framework. Effective February 16, 2026, Health Canada confirmed that new FSRN applications will no longer be accepted, existing FSRNs will be listed as discontinued, and foreign GMP evidence must now be submitted directly through the Canadian Site Licence pathway.
Why Health Canada Ended the FSRN Process
According to Health Canada’s February 2026 Site Licensing and GMP Inspection Bulletin, the NNHPD reviewed its foreign site assessment procedures and determined that the standalone FSRN process was no longer necessary. Instead, Health Canada has integrated the review of foreign GMP evidence directly into the existing Site Licence assessment system in their Red Tape Reduction initiative, meant to simplify submissions, reduce parallel processing streams, and focus resources on domestic site license-related applications.
These changes from Health Canada are meant to create a more efficient regulatory review process. However, this means that the burden of providing acceptable GMP evidence now falls more heavily on the site license applicant.
FSRN Is No Longer Accepted as GMP Support
Starting from February 16th, 2026, an FSRN Authorization form can no longer be used as an acceptable standalone GMP evidence option when filing a new Site Licence application, amendment, or renewal. Instead, Health Canada now expects the GMP evidence to be included in that submission.
Health Canada has specifically advised that foreign sites which previously relied on FSRN registration must now provide their GMP evidence through an associated Site Licence submission such as through a Canadian importer. Any new request for FSRN issuance will be rejected, and any applications that reference the FSRN as GMP evidence will be asked to provide alternative forms of evidence.
What Importers Will Need to Submit Instead
Without FSRN authorization, importers should expect to provide GMP documentation, which includes:
- foreign GMP certificates,
- third-party audit reports,
- Quality Assurance Reports,
- Standard operating procedures,
- and other records demonstrating alignment with Part 3 GMP requirements.
For companies managing multiple overseas suppliers, this may significantly increase regulatory coordination time, supplier follow-up, and technical document review prior to submission. If Health Canada has any observations related to those submitted documents, this would also increase the time needed to prepare responses to their Information Request Notices.
Strategic Impact on the NHP Industry
For Natural Health Product companies that rely on foreign contract manufacturers, private label facilities, or international packaging operations, this regulatory update creates both compliance risk and operational planning challenges.
Common concerns now include:
- longer timelines to add foreign sites,
- greater confidentiality concerns from overseas suppliers,
- increased likelihood of documentation gaps,
- and more internal resources needed for GMP evidence collection and assessment.
Companies that delay preparation may find that future Site Licence amendments become slower and more difficult than expected.
By contrast, organizations that proactively review foreign supplier documentation and build complete GMP evidence files in advance will be in a much stronger position to avoid filing interruptions.
Preparing for the Post-FSRN Environment
If importers want to ensure they are prepared to move away from these Foreign Site Reference Numbers, they should begin:
- identifying all foreign sites previously supported by FSRNs,
- confirming whether current GMP documentation is available,
- conducting technical gap assessments,
- and preparing future amendment packages using direct GMP evidence rather than Foreign Site Reference Numbers.
Need Support Updating Your Site Licence Strategy?
As Health Canada removes FSRN registration from the GMP evidence toolbox, submission readiness is becoming increasingly important for Canadian NHP importers.
Our regulatory team assists companies with:
- foreign GMP evidence reviews,
- Health Canada Site Licence amendments,
- Quality Assurance Report preparation,
- supplier documentation assessments,
- and complete NHP compliance strategy development.
If your company previously relied on FSRN-supported filings, now is the ideal time to transition to a stronger, submission-ready regulatory model.
Blog Author
Matthew Lai, H.BSc.
Matthew Lai is a Regulatory Affairs Specialist with expertise in natural health products, GMP requirements, and Health Canada site licensing. With experience in regulatory affairs and quality assurance, he supports clients in achieving compliance and ensuring product safety in the Canadian market.
